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Objective: The purpose of this study was to determine the incidence and significance of aneurysm enlargement, with or
without treatment, in relation to the primary end points of rupture, surgical conversion, aneurysm-related death, and
survival following endovascular repair.
Method: Aneurysm (AAA) size changes and clinical outcome of all patients treated from 1997 through 1998 during the
Phase II AneuRx multicenter clinical trial of endovascular AAA repair were reviewed. Aneurysm dimensions and the
presence or absence of endoleak were determined by an independent core laboratory, with enlargement or shrinkage
defined as a diameter change of 5 mm or more compared with baseline.
Results: Among 383 patients (89% men, 11% women, age 73  9 years), with a mean device implant time of 36  11
months (median  39 months), aneurysm diameter decreased from 5.7  1.0 at baseline to 5.2  1.0 at 3 years (P 
.0001). A total of 46 patients (12%) experienced AAA enlargement, 199 patients (52%) had no change in AAA diameter,
and 138 patients (36%) had a decrease in AAA diameter of 5 mm or more. Significant risk factors for enlargement
included age (enlargement patients were 4 years older on average than patients with aneurysms that decreased in size; P
 .002) and the presence of an endoleak (P < .001). Among patients with endoleak at any time, 17% had aneurysm
enlargement, whereas only 2% of patients without endoleak had aneurysm enlargement (P < .001). Patients with
enlargement were more likely to undergo secondary endovascular procedures and surgical conversions (P < .001).
Twenty patients (43%) with enlargement underwent treatment, and 26 patients were untreated. There were two deaths
following elective surgical conversion and one death in a patient with untreated enlargement and a type I endoleak. Three
aneurysms ruptured: one with enlargement, one with no change, and one with a decrease in aneurysm size; all three
aneurysms were larger than 6.5 cm. Kaplan-Meier analysis showed that freedom from rupture at 3 years was 98% with
enlargement, 99% with no change, and 99% with decrease in AAA size (log-rank test, not significant). Freedom from AAA
death at 3 years was 93% in patients with enlargement, 99% in no increase, and 99% in decrease (P  .005). Survival at
3 years was 86% with increase, 82% with no change, and 93% with decrease (P  .02).
Conclusions: Aneurysm enlargement following endovascular repair was not associated with an increased risk of aneurysm
rupture or decrease in patient survival during a 3-year observation period. Aneurysm size rather than enlargement may be
a more meaningful predictor of rupture. Close follow-up and a high re-intervention rate (43%) may account for the low
risk of rupture in patients with enlargement. The long-term significance of aneurysm enlargement following endovascular
repair remains to be determined. (J Vasc Surg 2004;39:109-17.)
Aortic aneurysms enlarge over time, with an increasing
risk of rupture directly related to aneurysm size.1-4 Al-
though the annual risk of rupture of small aneurysms 4 to 5
cm in diameter is relatively low (0.5%-5%), the annual risk
of rupture of 5- to 6-cm aneurysms is 3%-15%.5 If aneu-
rysms are untreated, the 1-year risk of rupture of 5.5- to
6.4-cm aneurysms is 10%, of 6.5- to 7.0-cm aneurysms is
19%, and of aneurysms greater than 7.0 cm is 33%.6 Al-
though the relationship between absolute aneurysm size
and rupture is well known, the significance of aneurysm
enlargement is less clear.5-8 Evidence of recent or rapid
aneurysm enlargement is thought to presage aneurysm
rupture and is commonly used as an indication for surgi-
cal9,10 or endovascular aneurysm treatment.11 However,
enlargement alone, independent of aneurysm size, has not
been found to predict the risk of rupture in prospective
clinical trials10 or surveillance studies of nonsurgical pa-
tients.6
Aortic aneurysms may increase in size following endo-
vascular repair, with or without the presence of an en-
doleak, but there are few data on the significance of this
finding, particularly with regard to the risk of rupture.
Although it is reassuring to see evidence of decreasing
aneurysm size with complete aneurysm exclusion, it is
disconcerting to note an endoleak and increase in aneurysm
size following endovascular repair, raising the specter of
possible rupture. These findings usually prompt secondary
endovascular treatment or conversion to open surgical an-
eurysm repair. However, there are no clear data confirming
that aneurysm enlargement alone increases the likelihood
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of rupture following endovascular repair independent of
other factors that may be important, such as fixation and
type I endoleak. Ruptures have been reported with all
endovascular devices and are often specifically related to the
endovascular device or its fixation to the aortic neck or iliac
arteries.12-21 Ruptures have been found in patients with no
endoleaks and decreasing aneurysm size, as well as in pa-
tients with endoleaks and increasing aneurysm size.13,22
Independent core laboratory evaluation of endoleaks in the
AneuRx clinical trial revealed that the presence of an en-
doleak following stent-graft repair was not a significant
predictor of primary or secondary outcome measures.23
Although the presence of an endoleak at 1 month was
associated with an increased likelihood of aneurysm en-
largement, it was not associated with aneurysm rupture
following the procedure.23 It was unclear whether aneu-
rysm enlargement with longer patient follow up would
become a meaningful predictor of risk of rupture following
endovascular repair.
The purpose of this investigation was to determine the
incidence and significance of aneurysm enlargement fol-
lowing endovascular repair and to relate this finding to the
primary objective of aneurysm treatment, namely, prevent-
ing aneurysm rupture. We used independent core labora-
tory documentation of changes in aneurysm size with a
mean follow-up time of 36 months after endovascular
repair.
METHOD
All patients treated with the AneuRx stent-graft system
(Medtronic AVE, Santa Rosa, Calif) during the phase II
clinical trial of endovascular aneurysm repair from April
1997 through September 1998 were reviewed. Thirteen
clinical sites (see Appendix, online only) enrolled and
treated 424 patients who met the inclusion criteria of the
trial as well as 46 patients who did not meet the inclusion
criteria and were treated on an “emergency use” basis, for a
total of 470 patients. Details of the study design and patient
eligibility have previously been published;24,25 selection
criteria included an abdominal aortic aneurysm (AAA) with
an infrarenal neck length of at least 10 mm and a neck
diameter between 18 and 26 mm with a maximum distal
iliac diameter of 15 mm. Patients were evaluated with
preprocedure and postprocedure contrast computed to-
mography (CT) scans with scheduled follow-up imaging at
1, 6, and 12 months and at yearly intervals thereafter.
Additional interval CT scans at more frequent intervals
were obtained as clinically indicated. An independent core
laboratory, which had no involvement with any of the
clinical investigation sites and was blinded from patient
identification and clinical information, interpreted CT
scans and abdominal radiographs submitted by the clinical
sites.
The core laboratory reported aortic aneurysm diameter
at each time point as the largest wall-to-wall diameter of the
aneurysm on cross-sectional contrast CT scans. The initial
postprocedure CT scan (predischarge CT, obtained within
4 days in 95% of patients),23 was used as the baseline for
determination of subsequent changes in aneurysm diame-
ter. An increase or decrease of maximum aneurysm diame-
ter of 5 mm or more, compared with the baseline scan at
any follow-up time point, was considered to be a significant
change in aneurysm size. Patients were assigned to the
increase or decrease group the first time their aneurysm size
met the 5-mm threshold of change. Patients remained in
that group regardless of subsequent changes in aneurysm
size due to therapy or other reasons. The core laboratory
also reported on the integrity of the stent graft, the pres-
ence or absence of an endoleak, and the dimensions of the
infrarenal aortic neck and iliac arteries. Clinical information
on each patient was reported by each of the 13 clinical sites
to a centralized data registry and was not available to the
core laboratory. Primary clinical end points included aneu-
rysm rupture (intraoperative, perioperative, and postoper-
ative ruptures), aneurysm-related death (any death within
30 days of a primary or secondary procedure related to
aneurysm rupture, thrombosis, or device failure), surgical
conversion (perioperative and late open surgical aneurysm
repair), and overall survival (death from any cause). Sec-
ondary procedures for any cause, including aneurysm en-
largement, endoleak, stent-graft migration, and graft limb
thrombosis, were recorded.
All patients were reviewed, with a clinical follow-up
data freeze as of August 2001. Patients who had both a
postprocedure CT scan and at least one follow-up CT scan,
which were evaluated and reported by the core laboratory
so that changes in aneurysm diameter could be determined,
are the subject of this report. A total of 383 patients met
these criteria. Patients were divided into three groups on
the basis of aneurysm diameter change from baseline dur-
ing the follow-up period: increase in diameter of 5 mm or
more, no change in diameter at any time, or decrease in
diameter of 5 mm or more.
Results were expressed as the mean and median 
standard deviation. Differences among the three patient
groups for all end points were determined by using analysis
of variance for continuous data and 2 and Fisher exact tests
for categorical data. Time-dependent data were analyzed by
using the Kaplan-Meier method and compared by using the
log-rank test. Differences with P  .05 were considered to
be significant.
RESULTS
Patient population. Among the population of 470
patients treated during the phase II AneuRx trial, 383
patients had two or more postprocedure core laboratory
measurements of maximum aortic aneurysm diameter so
that changes in aneurysm size could be determined. Eighty-
seven patients did not meet the inclusion criteria for this
study for the following reasons (listed hierarchically, with
each patient counted once): device not implanted, 9 pa-
tients; death within 30 days, 7 patients; surgical conversion,
3 patients; no core laboratory report of a postprocedure CT
scan, 43 patients; no core laboratory report of a follow-up
CT scan, 25 patients.
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Mean preoperative aortic aneurysm diameter among
the 383 patients was 5.7 1.0 cm (median, 5.5 1.0 cm),
and mean implant duration was 36  11 months (median,
39 months; range, 2-52 months). The mean number of
postprocedure CT scans per patient was 3.4  1.5 (range,
1-11 scans per patient). The number of CT scans with core
laboratory data at each time point along with mean and
median aneurysm diameters is shown in Table I. Mean
aneurysm diameter for the entire group decreased over the
3-year observation period to a mean diameter of 5.2  1.0
cm (median, 5.0 1.0 cm) at 3 years (P .001 compared
with baseline; Fig). Endoleak rate at 1 year was 20%, at 2
years was 21%, and at 3 years was 22%, with an endoleak
distribution of approximately 12% type I, 72% type II, 10%
type III, and 6% type IV in each year.
Aneurysm size changes. A total of 46 patients (12%)
experienced aneurysm enlargement, with an increase in
aneurysm size of 5 mm or more at some time during the
follow-up period; 199 patients (52%) had no change in
aneurysm size; and 138 patients (36%) had a decrease in
aneurysm size of 5 mm or more at some time during the
follow-up period (Table II). There were no significant
differences among the three patient groups with regard to
preoperative risk factors, with the exception that patients
with aneurysm enlargement were 4 years older on average
than patients with aneurysms that decreased in size (P 
.002). Changes in aneurysm size are shown in Table III.
There were no significant differences in aneurysm diameter
at baseline among patients with enlargement, and no
change or decrease in aneurysm size. Enlargement patients
had a mean increase in aneurysm size of 0.9 cm (range,
0.5-3.0 cm), whereas patients with shrinking aneurysms
had a mean decrease in size of 1.0 cm (range, 0.5-2.6 cm).
There was no difference in the mean rate of change in
aneurysm size among patients with enlarging aneurysms
(0.31 mm per month) and patients with shrinking aneu-
rysms (0.31 mm per month).
Endoleak and migration. Endoleaks were reported
by the core laboratory at some time during the follow-up
period in 54% of patients. Among patients with endoleak at
any time, 17% had aneurysm enlargement, whereas only 2%
of patients without endoleak had aneurysm enlargement (P
 .001). Patients with aneurysm enlargement were more
likely to have had an endoleak at some time following
device implantation (38 of 46 patients, 83%) than patients
with no change (113 of 196 patients, 58%) or patients with
a decrease in aneurysm size (54 of 136 patients, 40%; P 
.0001. At 1 year, 56% of patients with enlargement had
endoleaks, 23% of patients with no change in aneurysm size
had endoleaks, and 6% of patients with decreasing aneu-
rysm size had endoleaks (P  .0001; Table IV). This
distribution remained unchanged at the end of 3 years. The
majority of endoleaks (72%) were type II endoleaks, and
there was no difference in distribution of type I and type II
endoleaks among the three patient groups. Migration was
noted by the core laboratory in 24 of 383 patients (6%),
with no significant difference in migration rate among the
three patient groups (Table IV).
Secondary procedures. Secondary procedures were
performed in 70 of 383 patients (18%). Patients with
aneurysm enlargement were more likely to undergo a sec-
ondary procedure (21 of 46 patients, 46%) than patients
with no change (33 of 199 patients, 17%) or decreasing
aneurysm size (16 of 138 patients, 12%; P  .0001).
Secondary procedures in enlargement patients included
placement of proximal or distal stent-graft extender mod-
ules (10 patients), coil embolization for endoleaks (five
patients), treatment of graft-limb occlusions with femoral-
femoral bypass (four patients), and angioplasty and stenting
for iliac stenosis (two patients). Eight of the enlargement
patients who had secondary procedures had documented
aneurysm enlargement before the secondary procedure,
and seven had documented enlargement after the second-
ary treatment. Four enlargement patients who had second-
ary treatments subsequently underwent surgical conver-
sion. Kaplan-Meier estimates for freedom from secondary
procedures at 3 years were 62% for patients with aneurysm
enlargement, 83% for patients with no change, and 88% for
patients with decreasing aneurysm size (log-rank test, P 
.0001).
Surgical conversion. Open surgical aneurysm repair
was performed in 18 of 383 patients (4.7%). Of these, 9
surgical conversions were performed in patients with en-
largement, 7 were performed in patients with no change in
Mean abdominal aortic aneurysm diameter (cm). Mean time since
implantation 36  20 months.
Table I. Maximum aneurysm diameter (cm)—core
laboratory data (N  383)
Number Mean Median SD
Preoperative 322 5.7 5.5 1.0
Predischarge 383 5.7 5.6 1.0
6 months 334 5.6 5.5 1.0
1 year 313 5.4 5.2 1.0
2 years 234 5.3 5.3 1.1
3 years 79 5.2* 5.0 1.0
*Change from predischarge diameter, P  .0001, signed rank t-test.
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aneurysm size, and 2 were performed in patients with a
decrease in aneurysm size. Patients with aneurysm enlarge-
ment had a mean increase in diameter of 10  6 mm, with
a range of 5 to 20 mm before surgical conversion. Patients
with enlargement were more likely to undergo surgical
conversion (20%) than patients with no change (4%) or
decreasing aneurysm size (2%; P  .0001) (Table V).
However, 80% of patients with aneurysm enlargement have
not required surgical conversion. Four of the nine enlarge-
ment patients who underwent conversions had been
treated with a secondary endovascular procedure before
conversion. One patient had emergent conversion follow-
ing rupture and died in the postoperative period. Elective
surgical conversion for enlargement with type II endoleak
was performed in eight patients, with two postoperative
deaths (25%). Mean aneurysm diameter at the time of
elective conversion was 6.8 cm, with a range of 5.4 to 8.0
cm. One patient died after elective conversion at 33 months
for enlargement from 5.0 to 6.0 cm with a type II endoleak.
The second patient died at 25 months after elective surgical
conversion for enlargement from 7.5 to 8.0 with a type II
endoleak. Kaplan-Meier estimates for freedom from surgi-
cal conversion at 3 years were 81% for patients with aneu-
rysm enlargement, 96% for patients with no change, and
99% for patients with decreasing aneurysm size (log-rank
test, P  .0001) (Table VI).
Rupture. Three of the 383 patients (0.8%) had aneu-
rysm rupture, with one rupture in each of the three patient
Table II. Preoperative patient characteristics
Increase
n  46 (12%)
No change
n  199 (52%)
Decrease
n  138 (36%) P*
Age (y) 75  6 74  8 71  9 .002
Gender (male/female) 91%/9% 93%/7% 88%/12% NS
AAA diameter (cm) 5.5  0.7 5.7  1.0 5.7  1.0 NS
Family Hx of AAA 11% 8% 15% NS
Hypertension 65% 66% 59% NS
Diabetes 22% 13% 9% NS
Smoking 78% 82% 90% NS
Chronic obstructive
pulmonary disease
20% 25% 25% NS
Obesity 26% 16% 15% NS
Myocardial infarction 39% 39% 34% NS
Coronary intervention 48% 49% 40% NS
Prior stroke 4% 13% 10% NS
PVOD 17% 20% 18% NS
Cancer 33% 28% 19% NS
Chronic renal failure 2% 3% 1% NS
Abd surgery/radiation 37% 30% 25% NS
AAA, Abdominal aortic aneurysm; Hx, history; Abd, abdominal; PVOD, peripheral occlusive disease.
*Analysis of variance.






(n  138) P*
Preoperative 5.5  0.7 5.7  1.0 5.7  1.0 NS
Postimplant 5.6  0.9 5.7  0.9 5.8  1.0 NS
Max/min 3 years 6.4  1.0 5.5  5.8 4.7  1.0 .001
Max/min, Maximum/minimum.
*Analysis of variance.






(n  138) P*
Endoleak 6 months 23/40 (58%) 38/160 (24%) 15/116 (13%) .0001
Endoleak 1 year 20/36 (56%) 32/138 (23%) 7/111 (6%) .0001
Endoleak 2 years 16/31 (52%) 21/92 (23%) 6/81 (7%) .0001
Endoleak 3 years 6/9 (67%) 5/23 (22%) 4/35 (11%) .002
Migration anytime 1/46 (2%) 12/199 (6%) 11/138 (8%) NS
*Analysis of variance.
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groups. One patient had aneurysm enlargement of 5 mm at
1 year (6.5-7.0 cm); the aneurysm was 4 mm larger than
baseline at 16 months, with a type I iliac fixation endoleak.
This patient refused treatment and further follow-up and
experienced a rupture at 24 months at a nonstudy site
hospital. A CT scan before emergency surgery at the local
hospital demonstrated rupture with aneurysm diameter 6
mm larger than core laboratory baseline. One patient with
a 6.8-cm aneurysm had no change in aneurysm size and no
endoleak at 1 year. There was evidence of insecure proximal
fixation in a short angulated neck, however, and the aneu-
rysm ruptured at 14 months. One patient with a 9.0-cm
aneurysm had no endoleak and a decrease in aneurysm size
to 6.0 cm at 1 year. This aneurysm ruptured at 23 months
with evidence of increased angulation of the stent graft,
resulting in separation of the iliac junction limb at the time
of rupture. Thus all three rupture patients had large aneu-
rysms at baseline (6.5, 6.8, and 9.0 cm) and all three
rupture patients died following emergent surgical conver-
sion. Each had been treated with the early “stiff”-body
stent graft, which is no longer in use,24 and each had
evidence of insecure stent-graft fixation as the cause of
rupture.13 Kaplan-Meier estimates for freedom from aneu-
rysm rupture at 3 years were 98% for patients with aneurysm
enlargement, 99% for patients with no change, and 99% for
patients with decreasing aneurysm size (log-rank test, P 
0.8, ns) (Table VI).
AAA-related death. Five of the 383 patients (1.3%)
died of causes related to the aneurysm or stent graft. Three
of the five deaths were in patients with aneurysm enlarge-
ment: one after emergent conversion for rupture, and two
after elective surgical conversion for enlargement with Type
II endoleak. One patient with no change in aneurysm size
died after surgical conversion for rupture, and one patient
with a decrease in aneurysm diameter died after surgical
conversion for rupture. Kaplan-Meier estimates for free-
dom from AAA-related death at 3 years were 93% for
patients with aneurysm enlargement, 99% for patients with
no change, and 99% for patients with decreasing aneurysm
size (log-rank test, P  .005) (Table VI).
Survival. A total of 55 of the 383 patients (14%) have
died. More deaths have occurred in patients with no change
in aneurysm size (37 patients, 19%) than in patients with
enlarging (6 patients, 13%) or shrinking aneurysms (12
patients, 9%; P  .04). Three of the six deaths in the
enlargement group were aneurysm-related, and three were
unrelated (two cardiac and one cancer). Kaplan-Meier sur-
vival estimates at 3 years were 86% for patients with enlarge-
ment, 82% for patients with no change, and 93% for pa-
tients with decrease in aneurysm size (log-rank P  0.02)
(Table VI).
Predictors of changes in aneurysm size. Analysis of
variance revealed the following factors at baseline to be
significant predictors of change in aneurysm size following






(n  138) P*
Surgical conversion 9 (20%) 17 (4%) 2 (1.5%) .0001
Rupture 1 (2%) 1 (0.5%) 1 (0.7%) NS
AAA related death 3 (7%) 1 (0.5%) 1 (0.7%) .02
Death, any cause 6 (13%) 37 (19%) 12 (9%) .04
Secondary procedure 18 (39%) 33 (17%) 16 (12%) .0001
AAA, Abdominal aortic aneurysm.
*Analysis of variance.
Table VI. Summary of Kaplan-Meier estimates of primary end points
Freedom from rupture Increase No change Decrease P*
1 year 100% 100% 100%
2 year 98% 99% 99% Ns
3 year 98% 99% 99%
Freedom from AAA death
1 year 100% 100% 100% .005
2 year 98% 99% 99%
3 year 93% 99% 99%
Freedom from surgical conversion
1 year 100% 100% 100% .0001
2 year 95% 98% 99%
3 year 81% 96% 99%
Survival
1 year 100% 94% 100% .02
2 year 93% 85% 95%
3 year 86% 82% 93%
*Log-rank test.
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endovascular aneurysm repair: older age (P .002) and the
presence of an endoleak following device implantation (P
.001). Factors that were not predictive of aneurysm en-
largement included preoperative aneurysm size, infrarenal
neck diameter or length, iliac artery diameter, preoperative
patient characteristics and risk factors, stiff-body design,
stent-graft migration, and stent-graft patency.
Treatment of patients with enlargement. Mean im-
plant duration in the 46 patients with documented aneu-
rysm enlargement was 37  9 months (range, 7-50
months). Twenty of the 46 patients with enlargement
(43%) have undergone treatment: 5 patients have under-
gone elective surgical conversion, 3 patients have under-
gone surgical conversion after unsuccessful secondary treat-
ment, and 12 patients have undergone successful secondary
endovascular treatments. Twenty-six patients (57%) have
untreated enlargement, including seven patients with doc-
umented aneurysm enlargement of 5 mm or more after a
secondary treatment. Three patients with enlargement have
died of unrelated causes. Sixteen patients continue to be
followed with no secondary treatments, conversions, rup-
tures, or deaths.
There were no significant differences in age, preopera-
tive, or baseline patient characteristics among treated and
untreated patients. There were no differences in preopera-
tive aneurysm size or maximum aneurysm diameter at-
tained during the follow-up period, and no differences in
distribution of small and large aneurysms among treated
and untreated aneurysms (Table VII). The endoleak rates
were similar between the two groups at 1 year but increased
in years 2 and 3 in the treated group and decreased in the
untreated group. There was no significant difference in
migration rate or duration of follow-up after enlargement
was noted. Two patients in the treated group with enlarge-
ment and type II endoleaks died following elective surgical
conversion. One patient with enlargement who refused
treatment of a type I iliac endoleak experienced a rupture
and died following emergent conversion. There was no
difference in aneurysm-related death rate among treated
and untreated patients.
DISCUSSION
Endovascular treatment has been shown to be effective
in preventing aneurysm rupture in the great majority of
patients; however, aneurysm ruptures have been reported
following endovascular repair with all devices.26,27 Al-
though it is generally believed that a decrease in aneurysm
size along with the absence of an endoleak are reliable
indicators of success,28 the significance of failure of an
aneurysm to shrink after endovascular repair is unknown.
Numerous investigators have reported on size changes
following endovascular repair, with or without en-
doleaks.29-37 However, the true significance of aneurysm
size changes with respect to the primary end points of
aneurysm repair remains undefined. Indeed, aneurysm rup-
tures have been reported in patients with decreasing, in-
creasing, and stable aneurysm sizes following endovascular
repair,13,15,22 indicating that factors other than aneurysm
size changes may be the primary determinants of aneurysm
rupture.
In this study we found that 12% of patients experienced
aneurysm enlargement following endovascular repair at a
mean follow-up time of 3 years. The majority of aneurysms
did not change in size, and 36% of aneurysms decreased in
size. One patient with aneurysm enlargement of 5 mm, as
defined by independent core laboratory measurement, ex-
perienced aneurysm rupture, as did one patient with no
change in aneurysm size and one patient with a decrease in
aneurysm size. We thus could establish no relationship
between the risk of rupture and postprocedure aneurysm
diameter changes. All three ruptures occurred in patients
treated in the beginning of the trial with an early prototype
stiff bifurcation module that is no longer used, and each
rupture was attributed to a failure of primary device fixation
in the aortic neck, iliac artery, or modular device junction.13
Table VII. Treated versus untreated patients with AAA enlargement
Treated (n  20) Untreated (n  26) P
Age (y) 76  5 74  6 NS
Predischarge AAA diam (cm) 5.7  0.7 5.6  0.8 NS
Maximum AAA diam (cm) during follow up 20  9 6.4  1.1 NS
5.5 cm 1 4
5.5-5.9 cm 6 6
6.0-6.4 cm 2 5
6.5-6.9 cm 9 7
7.0 cm 2 4
Maximum AAA enlargement (cm) 0.9  0.4 0.8  0.4 NS
Time to enlargement (months) 20  9 14  9 .04
Follow-up time since enlargement (mo) 16  11 23  13 NS
Endoleak
1 year 11 of 17 (65%) 9 of 19 (47%) NS
2 years 10 of 13 (77%) 6 of 18 (33%) .02
3 years 5 of 5 (100%) 1 of 4 (25%) .05
Migration any time 1 of 20 (5%) 0 of 26 (0%) NS
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These observations indicate that mechanical factors and
issues related to endovascular device fixation may be of
importance and complicate this analysis of aneurysm size
changes and risk of rupture.
This is not to say that size changes are unimportant.
Indeed, aneurysm enlargement, particularly if associated
with a type I endoleak, may be an important indicator of
insecure device fixation that requires immediate treatment.
In this study, 43% of patients with enlargement required
secondary treatments or surgical conversion. The close and
ongoing surveillance of this group of patients along with
the high rate of intervention in patients with enlargement
may account for the low risk of rupture seen in this study.
Similarly, close surveillance and a high rate of intervention
was associated with a low risk of aneurysm rupture in
prospective, randomized clinical trials of small abdominal
aortic aneurysms.9,10 During both the United Kingdom
small aneurysm trial and the Veterans Affairs Aneurysm
Detection and Management Cooperative Study Group
trial, more than 60% of the surveillance patients were treated
with open surgical repair, thus avoiding potential rupture.
Although we documented aneurysm size (6-mm en-
largement) at the time of rupture in only one of the three
rupture patients, we cannot exclude the possibility that
significant enlargement may have occurred in the other two
rupture patients at some time after the last CT scan evalu-
ated by the core laboratory and before rupture. However,
our data indicate that patients with documented enlarge-
ment during surveillance following endovascular repair do
not seem to be at increased risk of rupture on this basis
alone. Similarly, patients with shrinking aneurysms noted
during surveillance do not seem to be protected from
rupture on this basis alone. Wolf38 has suggested that true
“regression” with protection from rupture does not occur
and that sudden re-exposure of the shrunken aneurysm to
pulsatile aortic flow, such as can occur if there is loss of
fixation or graft integrity, could cause sudden re-expansion
of the aneurysm and rupture. This may have been the case
in the patient in this study who experienced a rupture
despite a 3-cm decrease in aneurysm size. If it is assumed
that this 6-cm “shrunken” aneurysm re-expanded to its
original size of 9 cm when the iliac limb became discon-
nected, then the mean aneurysm size at the time of rupture
in the three rupture patients would be 7.8 cm. If the core
laboratory size of 6 cm is used for the size at the time of
rupture, then mean aneurysm size for the three ruptures
would be 6.8 cm. In any case, only large aneurysms rup-
tured in this experience, consistent with the well-known
relationship between aneurysm size and risk of rupture.
There were no ruptures in aneurysms 6 cm in diameter,
Aneurysm-related death is a primary long-term end
point of both open and endovascular aneurysm repair.28,39
Aneurysm-related death is defined as any death that occurs
within 30 days of the primary aneurysm treatment or within
30 days of any secondary treatment (or within the primary
hospitalization if longer), or any death related to the aneu-
rysm or graft or a surgical conversion at any time.28 In this
analysis, we included all patients treated during the AneuRx
Phase II trial who had core laboratory evaluation of aneu-
rysm size change, and we found five aneurysm-related
deaths among 383 patients. However, we excluded from
our patient cohort seven patients in the Phase II trial who
died within 30 days of the primary endovascular procedure
because core laboratory analysis of aneurysm size change
was not available in these patients. Had these seven aneu-
rysm-related deaths been included, the aneurysm-related
deaths for the entire Phase II and emergency use popula-
tion of 470 patients would be 98% at 1 year, 97.7% at 2
years, and 97.1% at 3 years, with 297 patients at risk at 3
years. This is similar to the aneurysm-related death rate for
the entire AneuRx patient cohort of 1193 patients treated
during Phases I, II, and III, including emergency-use pa-
tients,25,40 and is lower than the calculated aneurysm-
related death rates following open surgical repair.39,41-43
The aneurysm-related death rate for patients with enlarge-
ment included two deaths in patients with type II endoleak
enlargement of 5 to 6 cm and 7.5 to 8 cm and endoleak
who underwent elective surgical conversion. The mortality
rate for elective surgical conversion in enlargement patients
in this experience was 2 of 8 (25%), and this must be taken
into consideration when evaluating the risk of surgical
conversion versus continued observation of enlarging an-
eurysms in individual patients, particularly those with small
aneurysms.
The group of 46 patients with enlargement included 26
patients who were followed up with no treatment for an
average time of 23 months following documentation of
enlargement. There were no significant differences in en-
larged aneurysm size (6.4 cm), maximum amount of en-
largement, or duration of follow-up among untreated and
treated patients. The most remarkable difference was that
untreated patients had a declining endoleak rate from 47%
at 1 year to 25% at 3 years, whereas the treated group had an
increasing endoleak rate from 65% at 1 year to 100% at 3
years. There were two deaths in the treated group related to
elective surgical conversion and one death in the untreated
group related to rupture, highlighting the importance of
careful follow-up and clinical judgment in following up this
group of patients. The 1-year expected risk of rupture in
untreated 6.4-cm aneurysms is 10%.6 We observed one
rupture among 26 untreated patients (4%) over a 3-year
period, and this patient refused recommended treatment of
a type I endoleak. This indicates that continued observation
of some patients with aneurysm enlargement following
endovascular repair is a viable clinical option.
In this analysis we have included all patients treated
during Phase II in an intent-to-treat analysis. This includes
46 emergency-use patients who did not meet the inclusion
criteria for the Phase II study for a variety of reasons,
including not meeting the morphologic requirements of a
neck of at least 1 cm in length and iliac arteries 15 mm.
Thirty-two of these patients had core laboratory data and
are included in this report. The inclusion of these patients
did not influence the final results, and there were no differ-
ences in adverse events rates in these patients. Three of the
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46 patients who enlarged were emergency-use patients, and
none had ruptures or surgical conversion. There were no
aneurysm-related deaths in these patients.
Endoleaks are strongly associated with aneurysm en-
largement.26,33,36 In this study there was evidence of en-
doleak at some time during the follow-up in most patients
with enlargement. Although 38% of patients with shrinking
aneurysms also had documentation of endoleak at some
time following device implantation, only 2% had ongoing
endoleaks at 1 year. In contrast, 55% of enlargement pa-
tients had endoleaks at 1 year. However, most patients
(83%) with documented endoleak following endovascular
repair did not experience aneurysm enlargement and had
stable or decreasing aneurysm size. Only 17% of patients
with endoleak had evidence of aneurysm enlargement dur-
ing the course of the follow-up period. Furthermore, en-
doleak does not seem to be a significant predictor of
primary outcome measures after endovascular repair23—
particularly rupture. In this study two of the three patients
who had ruptures had no endoleak on core laboratory
analysis. This, however, does not rule out the possibility
that a new endoleak might have developed in these two
patients between the time of the last core laboratory eval-
uation and the subsequent rupture. Although it is often
assumed that endoleak, or endotension, is the predisposing
cause of rupture, other factors, such as intrinsic patient-
related biologic factors and aneurysm wall matrix metallo-
proteinase activity, may play larger roles in determining
aneurysm size changes and risk of rupture. Whereas the
causes of aneurysm enlargement remain unclear, it seems
that continued blood flow in the aneurysm sac, such as
exists with presence of a type I or a type II endoleak may be
required to facilitate aneurysm enlargement, even though it
may not have a causal relationship.32,34,36,44 It is interest-
ing to note that the factors that were not associated with
enlargement following endovascular repair included hyper-
tension, smoking, and chronic obstructive pulmonary dis-
ease, which have been identified as factors related to en-
largement of untreated aneurysms.42
Although the majority of aneurysms in this study did
not change in size (52%), the rate in change of enlarging
and shrinking aneurysms was the same (0.31 mm/mo) in
this study. This finding has previously been noted by
Wolf38 and is similar to the annual rate of enlargement of
0.36 mm/mo reported from the VA prospective surveil-
lance study of untreated aneurysms.6 Others have reported
similar rates of enlargement of untreated aneurysms, rang-
ing from 2.6 to 6.6 mm/y.8,29,44,45 However, enlargement
rate is not linear, and there is great variability and unpre-
dictability in enlargement rates of individual aneurysms.46
In clinical practice, significant aneurysm enlargement
following endovascular repair is a cause for concern, partic-
ularly when it is associated with type I endoleaks.26 Thus it
is not surprising that the rate of secondary procedures and
surgical conversions was significantly higher in the enlarge-
ment group. At a mean follow-up of 3 years, 20% of patients
had been converted to open surgical repair. However, it is
notable that 80% of patients have not required open surgi-
cal repair, and 57% of patients have not required any
additional treatment, despite aneurysm enlargement. Of
those who have required further intervention, the majority
have undergone endovascular treatment. The risk of rup-
ture appears to more likely be caused by aortic aneurysm
size rather than to the presence of 5 mm or more of
enlargement. Thus, careful clinical follow-up with serial
imaging and appropriate treatment as clinically indicated
appear to be successful in avoiding rupture in the vast
majority of patients. Indeed, rupture appears to be related
primarily to aneurysm size and to the security of stent-graft
fixation, rather than to the presence of endoleak or changes
in aneurysm size.13,24
CONCLUSION
Aneurysm enlargement of 5 mm or more occurs in 12%
of patients following endovascular repair with the AneuRx
stent graft. In our series, enlargement is associated with
increasing age and the presence of a persisting endoleak.
Patients with aneurysm enlargement are more likely to
undergo a secondary endovascular procedure or conversion
to open surgical repair than those without enlargement and
are at increased risk of aneurysm-related death. Patients
with enlargement do not appear to be at increased risk of
aneurysm rupture or decreased survival at a mean follow-up
time or at 3 years. Aneurysm size rather than aneurysm
enlargement may be a more important indicator of rupture
risk. However, longer follow-up is required to ascertain the
true long-term significance of aneurysm size changes fol-
lowing endovascular repair.
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